Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This botanical combination therapy was developed by Taichung Veterans General Hospital as an adjunctive treatment for allergic rhinitis. Administered as a nasal irrigation solution, the formulation consists of six traditional Chinese medicinal ingredients: Szechwan Lovage Rhizome (Ligusticum chuanxiong), Magnolia biondii flower bud (Xin Yi), Taiwan Angelica Root (Angelica dahurica), Wild Mint Herb (Mentha arvensis), Baikal Skullcap Root (Scutellaria baicalensis), and Borneol. These components are dissolved in warm normal saline for daily irrigation of the nasal cavity. The therapy is proposed to work through immune modulation and anti-inflammatory effects to alleviate severe allergic reactions and nasal congestion. It has been evaluated in a Phase 2 randomized, double-blind, placebo-controlled trial (NCT03443323) conducted by the hospital's Departments of Traditional Chinese Medicine and Otolaryngology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Szechwan Lovage Rhizome + Magnolia biondii flower bud + Taiwan Angelica Root + Wild Mint Herb + Baikal Skullcap Root + Borneol.